Indication
Macular Degeneration
16 clinical trials
16 products
1 drug
Product
E10030Product
BrolucizumabProduct
AfliberceptClinical trial
A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)Status: Completed, Estimated PCD: 2022-09-09
Clinical trial
A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the Induction and Maintenance Phase of TherapyStatus: Terminated, Estimated PCD: 2016-12-01
Product
FovistaProduct
volociximabClinical trial
A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2024-01-31
Clinical trial
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Product
VOY-101Product
SanhuangjingshimingwanClinical trial
A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )SubjectsStatus: Completed, Estimated PCD: 2022-11-01
Product
ElamipretideClinical trial
A Phase 2 Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Elamipretide in Subjects With Age-Related Macular Degeneration With Non-central Geographic AtrophyStatus: Completed, Estimated PCD: 2022-02-22
Clinical trial
A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From RetinopathyStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Product
CD34+ Bone Marrow Stem CellsClinical trial
A Prospective, Randomized, Double-masked, Controlled Study on Intravitreal Bevacizumab (Avastin) Versus Verteporfin (Visudyne) Photodynamic Therapy (PDT) for Patients With Neovascular Age-related Macular Degeneration (AMD)Status: Withdrawn, Estimated PCD: 2008-11-01
Product
BevacizumabProduct
VerteporfinClinical trial
Sildenafil for Treatment of Choroidal IschemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
SildenafilClinical trial
Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)Status: Active (not recruiting), Estimated PCD: 2019-12-01
Product
Omega-3 fatty acidsClinical trial
MMP-9 Inhibition for Recalcitrant Wet Age-Related Macular Degeneration (AMD)Status: Recruiting, Estimated PCD: 2023-12-31
Product
Doxycycline HyclateDrug
VarlilumabClinical trial
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal InjectionsStatus: Completed, Estimated PCD: 2018-02-01
Product
ProparacaineClinical trial
A Phase I/II Study to Evaluate the Tolerability, Safety and Efficacy of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD).Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
KH658